Nec extends to AI-driven health care, targets business value of $4.6B by 2030
In Parkinson's, adding NE3107 to levodopa aids motor, non-motor benefits
Neurastasis' non-invasive neurostimulator to improve stroke outcome
Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer's Disease Patients
New compound
Nitric oxide-modified proteins reveal sex differences in Alzheimer's
electromagnetic therapy
Methodological, target breadth begets optimism for movement disorder progress
BioVie Announces Additional Findings from Phase 2 Alzheimer's Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia
BioVie reports protocol deviations in Phase III Alzheimer's trial - Clinical Trials Arena
Intercept heads for FDA talks to 'Regenerate' filing for NASH hopeful obeticholic acid
BioVie (BIVI): Treating Alzheimer's, Parkinson's, Reversing The Biological Clock
BioVie Investor Deck, June 2021
Connex Biomedical Inc.
Biostage Inc.
